###### Strengths and limitations of this study

-   The cohort comprised a representative population-based sample in an area of ethnic, socioeconomic and educational diversity.

-   There was a comprehensive assessment of ophthalmic characteristics and risk factors at baseline and follow-up.

-   Data on mortality were collected through informant report, rather than from death certificates.

-   There was a high loss to follow-up in this study, raising the possibility of selection bias.

Introduction {#s1}
============

Visual impairment (VI) is common, affecting approximately 253 million people globally.[@R1] It can impact on different aspects of people's lives, including reducing quality of life, and increasing poverty and depression.[@R2] There is growing evidence from Europe, North America, Asia and Australia that VI and specific eye conditions are linked to increased risk of mortality,[@R6] but data are lacking for low-income and middle-income countries (LMICs), particularly from sub-Saharan Africa.

There are several potential pathways by which VI may be linked with mortality. Both VI and mortality are related to ageing, and so confounding or residual confounding may explain the reported associations. There are also common underlying risk factors for both VI and mortality, such as smoking, obesity and poverty. For instance, VI due to age-related macular degeneration (AMD) is more common among smokers,[@R18] and smoking increases risk of mortality. An underlying disease may also cause both VI and mortality, for instance, diabetic retinopathy (DR) is related to poor control of diabetes, which also causes increased mortality. People with VI may find it more difficult to seek healthcare, due to a range of barriers,[@R19] thereby increasing their mortality risk. Changes in the eye may be a marker of ageing or accelerated ageing,[@R20] and thereby linked to mortality. Finally, VI could acerbate frailty, depression and functional difficulties, all linked to increased mortality.[@R3]

It is important to explore whether there is an association between VI and mortality and, if there is, to identify possible pathways for this link, in order to understand how to reduce the vulnerability of people with VI to increased morbidity and mortality. Furthermore, these data may be useful to advocate for scaling up of eye health services in LMICs. The objective of this study was to investigate the association between VI and 6-year mortality risk within the Nakuru Eye Disease Cohort Study, a cohort of elderly Kenyan people.

Materials and methods {#s2}
=====================

The methodology of the Nakuru Eye Disease Cohort Study has been reported previously,[@R23] and is summarised here.

Baseline study population {#s2a}
-------------------------

The baseline population-based survey was conducted in 2007/2008. A total of 100 clusters each of 50 participants were selected with a probability proportional to the size of the population across Nakuru district. Households were selected within clusters using a modified compact segment sampling method.[@R24] Eligible individuals were those aged ≥50 years living in the household for at least 3 months in the previous year, and multiple subjects could be included per household.

Baseline ophthalmic and general examination {#s2b}
-------------------------------------------

All participants were invited to undergo a comprehensive ophthalmic examination at a screening clinic.[@R23] The objectives of the survey and the examination process were explained to those eligible in the local dialect, in the presence of a witness. A subject was examined only after informed written (or thumbprint) consent was obtained.

All participants underwent Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity (VA) testing on each eye separately and corrected VA (by refraction or pinhole) when less than 20/40 Snellen equivalent. Participants had two non-stereoscopic, digital, 45° fundus photographs (one disc and one macula centred) taken per eye by an ophthalmic clinical officer. Digital images were graded for the presence of AMD and DR at an approved grading centre (Moorfields Eye Hospital Reading Centre) by a senior grader, with adjudication by a clinician for confirmed cases and 5% of randomly selected images to ensure quality control. The presence of cataract was recorded by the ophthalmologist (WM) on slit-lamp examination after pupil dilation.

Detailed interviews were undertaken in the local language on demographic details, information on risk factors, socioeconomic status (SES) and full medical history.

A nurse performed and recorded measures of participants: height (Leicester Height Measure); weight (Seca 761) and three measures of blood pressure (Omron Digital Automatic Blood Pressure Monitor Model HEM907), each 10 min apart. Capillary blood was taken from all participants for random blood glucose (Accutrend GC system).

Assessment of vital status at follow-up {#s2c}
---------------------------------------

Follow-up was conducted from January 2013 to March 2014. A meeting was held approximately 1 week before the follow-up examination clinic for a given cluster. A list of study participants was given to the chief and a local village guide was recruited to assist location of the study participants. The village guide was someone who knew and was well known by the community (or the village chief him/herself). The advance team visited homes of baseline participants on the day prior to the examination clinic and confirmed their identity using the national identity cards and invited them to attend the examination clinic the following day. All identified participants were also asked to help locate baseline participants that had not been found.

Each local field guide was asked to classify the baseline study participant for that cluster as 'available', 'died', 'moved away' or 'unknown'. A participant was defined to have died if this was verified by at least two people from among the village chief, local guide or available study participant. Those who were known to have moved away were contacted when possible to either arrange follow-up at a more suitable location for the participant or to identify if they were alive or had died in the follow-up period. Any participant for whom nobody could identify as being alive or having moved away was recorded as 'unknown'.

Definitions and statistical analyses {#s2d}
------------------------------------

All participants who had complete examinations at baseline were considered 'at-risk' for mortality during follow-up. Follow-up status at 6 years was categorised as: (1) deceased (confirmed dead, as described above); (2) alive (ie, re-examined at follow-up, retraced but refused or unavailable at follow-up, or moved away but known to be alive) (3) unknown (ie, not retraced at follow-up, death not verified as described above or moved away but vital status unknown).

An SES score was developed based on information collected on job, housing conditions and ownership of material goods and livestock, based on previous work in the same population.[@R25] Hypertension was defined on the basis of the average of the second and third reading, with cut-offs used of systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or self-reported hypertension medication. Diabetes was defined as (1) self-reported in the history, or (2) random glucose of ≥11.0 mmol/L.

Statistical analysis was performed using STATA V.14 (Stata). All analyses accounted for the cluster survey design using Taylor linearised variance estimation to calculate standard errors. Pearson X^2^ tests corrected for the survey design were used to calculate p values to assess differences between participants whose mortality status is known and those where mortality status is unknown, that is, lost to follow-up (LTFU).

An inverse probability-weighting (IPW) model[@R26] was developed, in order to allow estimation of mortality risk while accounting for those LTFU. Multivariable logistic regression was used to identify independent baseline covariates associated with LTFU. Covariates for which there was the evidence of univariable association with the outcome (p\<0.10 across all categories of the variable) were kept in a multivariable model (age, sex, rural/urban and mother tongue). From this final model, the probability of being followed up was estimated, based on the presence or absence of each of these baseline covariates. The inverse of this probability formed the weighting to be applied to account for those LTFU.

The final step was to remove those individuals LTFU from the cohort, so that all subsequent analysis would be performed on only those with complete outcome records, with IPW applied to account for those LTFU. A sensitivity analyses for this approach involved repeating the analyses without applying IPW (ie, standard unweighted complete case analysis), and assessing the impact on the results.

Six-year mortality risk was calculated by dividing the number of deaths identified at follow-up by the number of people at risk at baseline. The 95% CIs were estimated assuming a Poisson distribution of events. This was done for the population overall, and stratified by each covariate.

Age/sex-adjusted risk ratios (RRs) for each covariate in relation to mortality were estimated using a Poisson regression model with robust error variance to allow for the clustered design and including IPW. Mortality status was the binary outcome and the distribution was assumed to be Poisson. These analyses were adjusted for the clustered design, as well as the use of IPW, by setting the clusters as the primary sampling unit and weighting using the inverse probability of being followed up. The model was further adjusted using a set of four SES variables only (SES quartile, location, ethnic group, education), then a set of five non-communicable disease (NCD) risk factors only (smoking, alcohol, diabetes, hypertension, body mass index (BMI)) before finally adjusting for all nine SES and NCD variables.

Patient and public involvement {#s2e}
------------------------------

Patients and the public were not directly involvement in the development of the research question and outcome measures, or the design or conduct of study. There are no plans to disseminate results directly to the study participants.

Results {#s3}
=======

At baseline, 4414 participants were examined. The follow-up assessment was conducted, on average, 5.6 years (SD 0.6) after the baseline, expressed for simplicity as 6 years (meaning that there were 6 years between the baseline and follow-up wave, rather than that each participant was followed up on average for 6 years as the time of LTFU or death was not known for individuals). Of the baseline participants, 3032 were known to be alive at follow-up (69% 2170 re-examined at the follow-up plus 862 known to be alive but not re-examined), 409 (9%) were known to have died and 973 had unknown vital status (22%).

[Table 1](#T1){ref-type="table"} provides the baseline characteristics of participants who had died during the follow-up, those were re-examined at follow-up and those who were LTFU. In comparison to those who had died, those who were re-examined were younger, more likely to be female, Kalenjin speakers, and had higher SES, while those of unknown status were more likely to be of 'other' tribes and urban residence.

###### 

Baseline characteristics of the Nakuru Eye Disease Cohort Study

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baseline characteristics                         Deceased\   Followed-up or known to be alive n=3032   P value[\*](#tblfn1){ref-type="fn"}   Unknown status\   P value[†](#tblfn2){ref-type="fn"}   
                                                   n=409                                                                                       n=973                                                  
  ------------------------------------------------ ----------- ----------------------------------------- ------------------------------------- ----------------- ------------------------------------ ---------
  Sex, % (n)                                       Female      42 (173)                                  53 (1612)                             \<0.001           53 (516)                             0.59

  Male                                             58 (236)    47 (1420)                                 47 (457)                                                                                     

  Tribe, % (n)                                     Kikuyu      69 (283)                                  62 (1881)                             0.02              61 (596)                             0.005

  Kalenjin                                         23 (93)     24 (736)                                  19 (186)                                                                                     

  Education, % (n)[‡](#tblfn3){ref-type="fn"}      None        6 (26)                                    9 (283)                               \<0.001           12 (114)                             0.21

  Primary                                          44 (179)    32 (952)                                  33 (323)                                                                                     

  Secondary                                        43 (174)    48 (1448)                                 44 (427)                                                                                     

  Higher                                           7 (29)      11 (327)                                  11 (105)                                                                                     

  Residence, % (n)                                 Rural       74 (303)                                  71 (2167)                             0.43              51 (498)                             \<0.001

  Urban                                            26 (106)    29 (865)                                  49 (475)                                                                                     

  SES quartile, % (n)[‡](#tblfn3){ref-type="fn"}   Lower       33 (136)                                  24 (709)                              0.002             26 (247)                             0.17

  Middle lower                                     24 (96)     26 (776)                                  23 (219)                                                                                     

  Middle upper                                     24 (97)     26 (777)                                  23 (218)                                                                                     

  Upper                                            19 (79)     24 (731)                                  29 (281)                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P value describes the strength of evidence that each variable is associated with mortality, among those where we know the mortality status (Null hypothesis is that the odds of death are equal in each category of the variable).

†P value describes the strength of evidence that each variable is associated with mortality status being missing (ie, comparison of known vs unknown mortality status). (Null hypothesis is that odds of knowing the mortality status of an individual at follow-up are equal in each group).

‡There were 27 missing values for education, and 48 missing values for SES.

SES, socioeconomic status.

[Table 2](#T2){ref-type="table"} shows the weighted 6-year mortality risk by level of VI. Overall, the 6-year mortality risk was 11.9% over 6 years. Risk increased with worsening levels of VI, from 9.7% (95% CI 8.4% to 11.1%) among those with normal vision to 38.5% (95% CI 24.5% to 54.8%) among those who were blind. This pattern was observed in both males and females, but was less clear in people aged \<60 years given the low mortality in this group and consequent small numbers. In each subgroup, the lowest risk of mortality was among people with normal vision. Mortality risk among people with VI was higher for males than for females, and among those ≥60 years vs \<60 years. Estimates changed little after weighting for LTFU ([online supplementary table](#SP1){ref-type="supplementary-material"} for unweighted estimates).
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###### 

The 6-year weighted mortality risk by level of visual impairment (VI) among the Nakuru Eye Disease Cohort Study Participants, stratified by age and gender

  Weighted using inverse probability-weights          Overall    Male            Female     \<60 years      ≥60 years                                                       
  --------------------------------------------------- ---------- --------------- ---------- --------------- ----------- --------------- --------- -------------- ---------- ---------------
  Visual acuity at baseline (better eye presenting)                                                                                                                         
  All individuals                                     409/3441   119 (106 134)   236/1656   143 (123 165)   173/1785    98 (84 113)     86/1503   56 (4570)      323/1938   169 (151 188)
  Normal (≥6/12)                                      280/2901   97 (84 111)     162/1378   118 (98 142)    118/1523    77 (6493)       78/1420   54 (4268)      202/1481   138 (120 159)
  Near normal (\<6/12 to ≥6/18)                       27/170     158 (107 226)   14/84      168 (104 258)   13/86       148 (85 245)    3/27      106 (32 301)   24/143     168 (114 241)
  VI (\<6/18 to ≥6/60)                                77/275     283 (236 336)   45/142     316 (252 388)   32/133      249 (178 338)   3/31      99 (31 271)    74/244     307 (252 368)
  Severe VI (\<6/60 to ≥3/60)                         4/16       260 (86 566)    2/10       187 (34 603)    2/6         379 (51 875)    2/2       --             2/14       136 (27 475)
  Blind (\<3/60)                                      19/50      385 (245 548)   13/30      436 (247 646)   6/20        310 (133 570)   0/6       --             19/44      438 (279 612)
  Any VI (\<6/18)                                     100/341    297 (248 351)   60/182     328 (268 395)   40/159      262 (191 347)   5/39      137(57 297)    95/302     318 (262 380)

Compared with those with normal vision (VA \>6/12, risk=9.7%), the mortality risk was significantly higher among people with VI (VA \<6/18 to ≥6/60; risk=28.3%; RR 1.75, 95% CI 1.28 to 2.40) or severe VI (SVI)/blindness (VA \<6/60: risk=34.9%; RR 1.98, 95% CI 1.04 to 3.80) ([table 3](#T3){ref-type="table"}). There was a weakening of the association after adjustment for NCD risk factors or full adjustment for both SES and NCD risk factors, although the overall trends between worsening vision and increased 6-year mortality risk remained evident (VI: RR 1.56, 95% CI 1.14 to 2.15; SVI/blind: RR 1.46, 95% CI 0.80 to 2.68).

###### 

Association between visual acuity (VA) category and 6-year mortality risk

  VA category                     Age/sex-adjusted RR   Age/sex, SES[\*](#tblfn5){ref-type="fn"} adjusted RR   Age/sex, NCD risk[†](#tblfn6){ref-type="fn"} factor adjusted RR   Fully adjusted ‡ RR
  ------------------------------- --------------------- ------------------------------------------------------ ----------------------------------------------------------------- ---------------------
  Normal (≥6/12)                  Reference             Reference                                              Reference                                                         Reference
  Near normal (\<6/12 to ≥6/18)   0.92 (0.57--1.50)     0.84 (0.51--1.39)                                      0.87 (0.51--1.48)                                                 0.82 (0.48--1.41)
  VI (\<6/18 to ≥6/60)            1.75 (1.28--2.40)     1.77 (1.30--2.40)                                      1.56 (1.13--2.16)                                                 1.56 (1.14--2.15)
  SVI/blind (\<6/60)              1.98 (1.04--3.80)     1.95 (1.01--3.76)                                      1.51 (0.82--2.77)                                                 1.46 (0.80--2.68)
  P value                         0.004                 0.003                                                  0.04                                                              0.03

\*SES=SES quartile, location, ethnic group, education.

†NCD risk factor=smoking, alcohol, diabetes, hypertension, BMI.

‡Age--sex, plus all SES and NCD risk factors.

BMI, body mass index; NCD, non-communicable disease; RR, risk ratio; SES, socioeconomic status; SVI, severe visual impairment; VI, visual impairment.

People with any VI had a higher mortality risk than those without VI (29.7% vs 9.7%; RR 1.54, 95% CI 1.22 to 1.93), and this association remained after adjustment for SES and NCD risk factors (RR 1.37, 95% CI 1.10 to 1.71) ([table 4](#T4){ref-type="table"}). Other risk factors associated with 6-year mortality risk after comprehensive adjustment included increasing age (oldest vs youngest age group: RR 4.68, 95% CI 3.55 to 6.18) and diabetes (RR 2.34, 95% CI 1.81 to 3.03). Being underweight was associated with an increased 6-year mortality risk (underweight vs normal: RR 1.60, 95% CI 1.24 to 2.07).

###### 

Multivariable analysis of baseline covariables and 6-year mortality risk in the Nakuru Eye Disease Cohort Study

                                   No at risk   Deaths   Risk per 1000/6 years (95% CI)   Age/sex- adjusted risk ratio   Age/sex/socioeconomic status (SES) adjusted risk ratio   Age/sex/SES- non-communicable disease (NCD) risk factor adjusted risk ratio
  -------------------------------- ------------ -------- -------------------------------- ------------------------------ -------------------------------------------------------- -----------------------------------------------------------------------------
  Any visual impairment (\<6/18)                                                                                                                                                  
   No                              3071         307      100 (87 to 115)                  Reference                      Reference                                                Reference
   Yes                             341          100      297 (248 to 351)                 1.54 (1.22 to 1.93)            1.55 (1.24 to 1.94)                                      1.37 (1.10 to 1.71)
  Gender                                                                                                                                                                          
   Male                            1656         236      143 (123 to 165)                 Reference                      Reference                                                Reference
   Female                          1785         173      98 (84 to 113)                   0.74 (0.63 to 0.87)            0.68 (0.56 to 0.83)                                      0.82 (0.63 to 1.06)
  Age                                                                                                                                                                             
   50--59                          1503         86       56 (45 to 70)                    Reference                      Reference                                                Reference
   60--69                          1036         96       94 (77 to 115)                   1.64 (1.24 to 2.17)            1.58 (1.19 to 2.09)                                      1.40 (1.07 to 1.83)
   70--79                          571          107      191 (161 to 224)                 3.27 (2.55 to 4.20)            3.15 (2.39 to 4.15)                                      2.74 (2.09 to 3.60)
   80+                             331          120      363 (311 to 419)                 6.36 (4.85 to 8.33)            5.76 (4.39 to 7.57)                                      4.68 (3.55 to 6.18)
  SES risk factors                                                                                                                                                                
   Location                                                                                                                                                                       
   Rural                           2470         303      123 (108 to 140)                 Reference                      Reference                                                Reference
   Urban                           971          106      110 (83 to 145)                  1.14 (0.90 to 1.45)            1.15 (0.90 to1.48)                                       1.18 (0.91 to 1.53)
   SES quartile                                                                                                                                                                   
   Lower                           845          136      164 (137 to 197)                 Reference                      Reference                                                Reference
   Lower middle                    872          96       110 (91 to 134)                  0.75 (0.60 to 0.93)            0.72 (0.58to 0.91)                                       0.75 (0.59 to 0.95)
   Upper middle                    874          97       110 (89 to 134)                  0.86 (0.66 to 1.11)            0.82 (0.63 to 1.06)                                      0.84 (0.65 to 1.09)
   Upper                           810          79       99 (78 to 126)                   0.89 (0.69 to 1.14)            0.78 (0.58 to 1.05)                                      0.76 (0.56 to 1.03)
  Ethnic group                                                                                                                                                                    
   Kikuyu                          2164         283      131 (116 to 148)                 Reference                      Reference                                                Reference
   Kalenjin                        829          93       113 (91 to 139)                  0.83 (0.66 to 1.03)            0.78 (0.62 to 0.99)                                      0.81 (0.63 to 1.04)
   Other                           448          33       76 (48 to 119)                   0.84 (0.56 to 1.26)            0.82 (0.55 to 1.21)                                      0.81 (0.55 to 1.20)
   Education                                                                                                                                                                      
   No education                    309          26       86 (58 to 125)                   Reference                      Reference                                                Reference
   Primary                         1131         179      161 (138 to 188)                 0.95 (0.65 to 1.41)            0.96 (0.63 to 1.46)                                      0.97 (0.63 to 1.50)
   Secondary                       1622         174      107 (91 to 125)                  0.85 (0.59 to 1.22)            0.84 (0.57,1.24)                                         0.87 (0.59 to 1.28)
   College/Uni                     356          29       81 (52 to 124)                   0.94 (0.57 to 1.55)            0.95 (0.57 to 1.55)                                      1.01 (0.62 to 1.64)
  Risk factors for NCD                                                                                                                                                            
   Smoking                                                                                                                                                                        
   Never                           2396         256      107 (92 to 124)                  Reference                      Reference                                                Reference
   Former                          252          33       131 (93 to 180)                  1.20 (0.85 to 1.69)            1.20 (0.85 to 1.71)                                      1.15 (0.79 to 1.66)
   Current                         775          120      156 (132 to 184)                 1.19 (0.93 to 1.52)            1.17 (0.91 to 1.50)                                      1.19 (0.91 to 1.55)
   Diabetes                                                                                                                                                                       
   No                              3202         354      111 (98 to 125)                  Reference                      Reference                                                Reference
   Yes                             216          54       248 (194 to 313)                 2.16 (1.69 to 2.77)            2.20 (1.69 to 2.84)                                      2.34 (1.81 to 3.03)
   Hypertension                                                                                                                                                                   
   No                              1670         179      108 (92 to 126)                  Reference                      Reference                                                Reference
   Yes                             1737         229      132 (113 to 53)                  1.08 (0.90 to 1.29)            1.06 (0.88 to 1.28)                                      1.11 (0.92 to 1.34)
   Alcohol                                                                                                                                                                        
   Never                           1335         117      87 (73 to 104)                   Reference                      Reference                                                Reference
   Former                          1520         221      147 (125 to 171)                 1.18 (0.95 to 1.48)            1.18 (0.94 to 1.49)                                      1.15 (0.90 to 1.46)
   Current                         559          70       125 (100 to 157)                 1.15 (0.86 to 1.53)            1.18 (0.87 to 1.60)                                      1.08 (0.77 to 1.51)
   Body mass index                                                                                                                                                                
   Underweight                     468          99       216 (169 to 271)                 1.55 (1.20 to 2.00)            1.57 (1.22 to 2.02)                                      1.60 (1.24 to 2.07)
   Normal                          1697         199      117 (101 to 136)                 Reference                      Reference                                                Reference
   Overweight                      779          66       86 (66 to 111)                   0.90 (0.69 to 1.18)            0.87 (0.66 to 1.14)                                      0.81 (0.62 to 1.05)
   Obese                           447          32       73 (52 to 100)                   0.89 (0.63 to1.25)             0.86 (0.59 to 1.24)                                      0.83 (0.57 to1.20)

Risk of mortality was analysed by prevalence of specific eye diseases at baseline ([table 5](#T5){ref-type="table"}). The presence of cataract (or aphakia/pseudophakia) and any VI (ie, VA \<6/18 in better eye) was associated with higher mortality risk (RR 1.57, 95% CI 1.24 to 1.98), whereas cataract alone (or aphakia/pseudophakia) was not (RR 1.26, 95% CI 0.95 to 1.66). Mortality risk was higher among people with AMD at baseline (with or without VI), compared with those without, although these associations were not statistically significant (RR 1.42, 95% CI 0.91 to 2.22 and RR 1.34, 95% CI 0.99 to 1.81, respectively). DR was associated with a threefold increased mortality risk (RR 3.18, 95% CI 1.98 to 5.09). The number of people with DR and any VI was too small to make meaningful inferences.

###### 

Risk of mortality during 6 years of follow-up by the presence of specific eye diseases at baseline

                                                         No at risk   Deaths   Risk per 1000/6 years (95% CI)   Age/sex- adjusted risk ratio
  ------------------------------------------------------ ------------ -------- -------------------------------- ------------------------------
  Cataract present                                                                                              
   No                                                    1921         142      72.5 (59.1 to 88.6)              Reference
   Yes                                                   1478         265      181.3 (161.6 to 202.8)           1.26 (0.95 to 1.66)
  Cataract and visual impairment (VI) present (\<6/18)                                                          
   No                                                    3103         313      100.7 (87.5 to 115.5)            Reference
   Yes                                                   296          94       322 (267.3 to 381.8)             1.57 (1.24 to 1.98)
  Age-related macular degeneration (AMD) present                                                                
   No                                                    2270         225      99.2 (83.3 to 117.8)             Reference
   Yes                                                   319          57       183.4 (141.3 to 234.5)           1.34 (0.99 to 1.81)
  AMD and VI present (\<6/18)                                                                                   
   No                                                    2529         265      105.5 (89.9 to 123.4)            Reference
   Yes                                                   60           17       282.7 (178.5 to 416.8)           1.42 (0.91 to 2.22)
  Diabetic retinopathy (DR) present                                                                             
   No                                                    2513         264      105.7 (90.4 to 123.3)            Reference
   Yes                                                   55           18       318.4 (199.4 to 467.0)           3.18 (1.98 to 5.09)
  DR and VI present (\<6/18)                                                                                    
   No                                                    2563         280      109.9 (94.1 to 128.0)            Reference
   Yes                                                   5            2        401.6 (37.5 to 920.4)            2.54 (0.57 to 11.36)

Discussion {#s4}
==========

VI was associated with increased mortality risk during 6 years of follow-up in a cohort of elderly Kenyan people. The risk of mortality increased with worsening vision. This association was reduced after adjustment for the presence of NCD risk factors, and to a lesser extent for SES indicators. Among eye conditions, DR was most strongly associated with mortality risk, although the number affected was small. Cataract with VI was also associated with elevated mortality, as were AMD and cataract without visual loss at baseline (although these estimates lacked precision).

Previous studies have also shown a positive relationship between VI and mortality, with evidence available from the USA,[@R6] UK,[@R10] Australia,[@R11] Japan,[@R13] Singapore,[@R14] China[@R16] and India.[@R17] Others have failed to find evidence for this association, including in India,[@R27] Iceland[@R28] and Taiwan.[@R29] Data from LMICs are sparse, in particular for sub-Saharan Africa, and so comparison of our study findings to those from similar settings is not possible.

On the basis of our findings, and those in the wider literature, consideration can be given to the potential pathway for the association between VI and mortality. There was clear evidence for confounding by age, as both VI and mortality are independently related to older age. Consequently, imperfect adjustment for age may have allowed for residual confounding as a partial explanation for the association. There was little evidence for confounding by SES, although in this setting high SES was associated with greater prevalence of NCD risk factors,[@R30] and a somewhat reduced mortality risk. The presence of NCD risk factors may also act as confounders of the association of VI on mortality, since the association was attenuated after adjustment for these indicators, as found in other studies.[@R10] Significant associations persisted, however, between VI and mortality after comprehensive multivariable adjustment in this study, as occurred in previous studies,[@R12] suggesting that residual confounding or direct effects of VI on mortality may be operational.

Exploring the relationship between different eye conditions and mortality may help to clarify whether independent biological pathways exist. DR is known to be associated with increased mortality,[@R15] as was also shown in this study. This link is unsurprising given the well-known relationship between uncontrolled diabetes with both DR and mortality. However, the relatively small number of people with DR in this population means that this link cannot be the sole driver of the VI-mortality association. Our study, as well as others, has shown cataract to be associated with increased mortality,[@R6] though this association is not always demonstrated.[@R15] Some studies have suggested that this relationship varies by cataract type.[@R8] It is hypothesised that the association between cataract and mortality arises as lens opacification (cataract) is an indicator of accelerated ageing.[@R20] The evidence for a link between AMD and mortality is more complex; some studies show that late AMD is associated with mortality, but not early AMD.[@R6] Others found no association between AMD and mortality,[@R15] or only among women.[@R43]

There are other potential pathways between VI and mortality not explored in this study. For example, NCD risk factors may be mediators of the effect of VI on mortality (rather than confounders) for reasons such as lower ability to access NCD treatment, less exercise, poorer diets and so on. Consequently, the association between VI and mortality adjusted by NCD risk factors would be an underestimate of the total effect. There were also concerns about the accuracy of assessment of visual fields in this population. Consequently, it was not possible to determine the presence of glaucoma at baseline, although others have suggested a link between glaucoma and mortality.[@R15] We also did not assess the impact of VI in accessing healthcare, although the Australian Blue mountain study showed that difficulties in walking explained some of the link between VI and mortality.[@R11] Only 18 people with cataract underwent cataract surgery during the follow-up period, so it was not possible to assess the impact on mortality.

There are several further limitations of the study, which need to be considered when interpreting the findings. There was a lack of data on date of death, and no verification from death certificates, as these are rarely available in many African settings,[@R45] including Kenya. Cause of death could not be determined, and so we could not assess whether the relationship was stronger between VI and specific causes of mortality, notably cardiovascular and non-cancer causes, as demonstrated in previous studies,[@R15] which would lend weight to a biological pathway for the association. The follow-up study was conducted after a period of postelection violence in the area. Consequently, there was a high LTFU in this study, raising the possibility of selection bias influencing the findings, although patterns changed little after weighting for LTFU. We did not adjust for the population sampling weights in our analysis, and so there could be concerns about the representativeness of the sample, although the selected sample had a similar demographic distribution to the general population.[@R49] Furthermore, the mortality rate may have been higher in this period, due to violence, and may have biased the association with VI if these deaths were disproportionally among people with VI, or among younger people (with lower prevalence of VI). Date of LTFU or death was not recorded, and so survival analysis was not possible. Another concern is that reports of local informants were used to categorise some people who had moved away as 'known to be alive', which may have created inaccuracies. The study may have been underpowered for some of the subgroup analyses, such as assessing the link between type of eye disease and mortality. We did not evaluate the association of different subtypes of AMD or cataract in relation to mortality because of small numbers. VI classification did not include loss of visual fields, and so the prevalence of functionally significant sight loss may have been underestimated. Self-reported diabetes was not confirmed (eg, from medical records). In terms of strengths, this was the first study of its kind in sub-Saharan Africa to assess the association between VI and mortality. The study participants comprised a representative population-based sample in an area of ethnic, SES and educational diversity. There was a comprehensive assessment of ophthalmic characteristics and risk factors at baseline, and every attempt was made to follow up all participants, and to record vital status.

In conclusion, VA was related to 6-year mortality risk in this cohort of elderly Kenyan people. The most likely explanation for the association is that both VI and mortality are related to ageing and NCD risk factors. The implication is that continuity of care is needed, as people with VI require linkages to preventative and treatment services. Furthermore, we must advocate for the scale-up of eye care services in Kenya, as VI is linked to premature mortality.
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